Previous close | 966.80 |
Open | 960.20 |
Bid | 933.00 x 0 |
Ask | 1,044.00 x 0 |
Day's range | 954.00 - 965.60 |
52-week range | 887.00 - 1,316.75 |
Volume | |
Avg. volume | 3,799,984 |
Market cap | 8.409B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 40.08 |
EPS (TTM) | 0.24 |
Earnings date | 27 Feb 2024 |
Forward dividend & yield | 0.30 (3.13%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | 12.87 |
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip
This powerhouse FTSE stock has embarked on a new growth strategy that’s already showing good results, but it looks undervalued to me. The post Down 27%, but set for major growth, this hidden FTSE gem looks cheap to me appeared first on The Motley Fool UK.
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons -